Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Phase I/II Study: AZD4360 in CLDN18.2-Positive Advanced Solid Tumors
AstraZeneca is evaluating AZD4360—a CLDN18.2 and CD3 directed bispecific antibody—as monotherapy in adult patients with locally advanced or metastatic solid tumors (gastric/GEJ, biliary tract, and PDAC) that express…
NCT06921928 - New trial
Multiple solid tumors
Phase I Study: BAY 3713372 in MTAP-deleted Solid Tumors
Bayer is conducting a first-in-human dose-escalation study to evaluate BAY 3713372—a novel second-generation PRMT5 inhibitor targeting MTAP-deleted solid tumors. The study will assess the safety, tolerability,…
NCT06914128 - New trial
Other blood cancers and transplant
Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged AML
Ohio State University is investigating whether ziftomenib, a menin-MLL inhibitor taken daily in 28-day cycles, can effectively treat patients with NPM1-mutated or KMT2A-rearranged AML who are not eligible for…
NCT06930352 - New trial
Other blood cancers and transplant
Phase I Study: BAFF CAR-T Cells (LMY-920) in Relapsed/Refractory CLL
Cleveland Clinic is investigating BAFF-ligand CAR T cells (LMY-920) following B-cell depletion with obinutuzumab, along with cyclophosphamide and fludarabine, in heavily pre-treated CLL patients to overcome…
NCT06916767 - New trial
Other blood cancers and transplant
Sequential Decitabine with FLAG-Ida and RIC HCT for High-Risk Myeloid Malignancies
Fred Hutchinson Cancer Center is evaluating a sequential regimen that combines decitabine with FLAG-Ida chemotherapy and reduced-intensity conditioning using total body irradiation, followed immediately by an…
NCT06928662 - New trial
Other blood cancers and transplant
Phase 1 Study: Allogeneic Anti-CD7 CAR-T (BEAM-201) in Relapsed/Refractory T-ALL/T-LLy
Children's Hospital of Philadelphia is evaluating BEAM-201, an allogeneic anti-CD7 CAR-T cell therapy, to determine its safety, tolerability, and preliminary efficacy in patients with relapsed/refractory T-cell acute…
NCT06934382 - New trial
Other blood cancers and transplant
Phase 1 Study: STX-0712 in Advanced Hematologic Malignancies
Solu Therapeutics, Inc is conducting a first-in-human, open‐label trial evaluating STX-0712 in patients with advanced CMML and AML who have exhausted available treatment options. Using a dose escalation and expansion…
NCT06950034 - New trial
Other blood cancers and transplant
Phase 1/1b Study of CER-1236 in Relapsed/Refractory AML and TP53-mutated or MRD-Positive Disease
CERo Therapeutics Holdings, Inc. is evaluating CER-1236—an autologous chimeric engulfment receptor T-cell therapy—in a first-in-human, open-label phase 1/1b study for patients with relapsed/refractory AML, including…
NCT06834282 - Trial result
Non-small cell lung cancer
Perioperative CTC Changes Predict Early Relapse in Resectable NSCLC
In a study of 99 patients with resectable NSCLC stratified by lymph node status, specific perioperative shifts in circulating tumor cell counts were linked to disease-free survival. In early-stage cases (cohort…
- Trial result
Non-small cell lung cancer
Divarasib Plus Migoprotafib: A Dual-Target Strategy Showing Encouraging Efficacy in KRAS G12C NSCLC
In this phase I study, combination therapy with divarasib—a next-generation KRAS G12C inhibitor—and migoprotafib—a SHP2 inhibitor—demonstrated an acceptable safety profile and promising antitumor activity in KRAS…
- Trial result
Non-small cell lung cancer
Trop-2 Expression Uncoupled from Efficacy in SG + Pembrolizumab ± Carboplatin for mNSCLC
In EVOKE-02, metastatic NSCLC patients without actionable genomic alterations exhibited high Trop-2 levels, yet objective response rates and progression-free survival were similar regardless of whether tumor Trop-2…
- Trial result
Non-small cell lung cancer
D3S-001 Breaks Through Resistance in KRAS G12C Inhibitor-Resistant NSCLC
In a Phase 2 trial, D3S-001—a next-generation GDP-bound KRAS G12C inhibitor engineered for rapid and complete target engagement—was administered as monotherapy to 20 NSCLC patients who progressed on prior KRAS G12C…
- Trial result
Non-small cell lung cancer
Daraxonrasib Shows Promise in NSCLC: Early ctDNA Clearance Linked to Improved Outcomes
In this Phase 1 study of daraxonrasib for RAS G12X mutant NSCLC, paired plasma samples revealed that complete clearance of ctDNA by Day 1 of Cycle 2/3 was observed in 89% of responders and 70% of patients with stable…
- New trial
Non-small cell lung cancer
Phase II Trial Combines Photoimmunotherapy with Anti-PD1 in Advanced NSCLC
Roswell Park Cancer Institute is evaluating ASP-1929 photoimmunotherapy paired with cemiplimab in patients with refractory, inoperable, or metastatic stage IIIB–IV NSCLC. This study employs a targeted approach where…
NCT06943664 - Trial result
Head and neck cancer
KN-B10 Emerges as a Strong Contender in First-Line Treatment for R/M HNSCC
An indirect treatment comparison using matched patient-level data from KEYNOTE-B10 and six pivotal trials revealed that pembrolizumab plus carboplatin and paclitaxel (KN-B10) delivers comparable or superior objective…
- Trial result
Head and neck cancer
Tolinapant and Radiation Combine to Offer a Platinum-Free Option for Advanced HNSCC
In this early-phase, single-arm trial, cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma received definitive radiation therapy alongside tolinapant, an IAP antagonist, with…
- Trial result
Head and neck cancer
Penpulimab Plus Chemotherapy Significantly Prolongs PFS in Global NPC Trial
In the AK105-304 Phase 3 trial, penpulimab combined with gemcitabine and cisplatin/carboplatin showed a statistically significant improvement in progression‑free survival (9.6 vs. 7.0 months; HR=0.45) versus placebo…
- New trial
Head and neck cancer
Phase II Chemoimmunotherapy Combining Nivolumab with Standard Chemo in Newly Diagnosed NPC
The National Cancer Institute is evaluating the addition of nivolumab to gemcitabine and cisplatin chemotherapy, followed by radiation, for patients with stage II–IV nasopharyngeal carcinoma. This innovative trial…
NCT06064097 - New trial
Head and neck cancer
Phase 2 Platform Study of Novel Combination Therapies in HNSCC
Gilead Sciences is leading a master protocol trial evaluating innovative regimens for metastatic or recurrent head and neck squamous cell carcinoma. The study tests two investigational arms—DOM plus ZIM with…
NCT06727565 - Trial result
Lymphoma
Evorpacept Plus R2 Achieves Remarkable Complete Response Rates in Relapsed/Refractory B‑Cell NHL
In this phase I study of 20 patients with relapsed/refractory B‑cell non‑Hodgkin lymphoma, the combination of evorpacept (a potent CD47 blocker) with lenalidomide and rituximab demonstrated a 90% overall response…
- New trial
Lymphoma
Phase III Trial Compares Tisagenlecleucel Versus Standard Therapy in r/r Follicular Lymphoma
Novartis is leading a multi-center trial that randomizes adult r/r follicular lymphoma patients to receive either a single infusion of CD19-directed CAR-T cell therapy (tisagenlecleucel) or standard regimens (R2 or…
NCT05888493 - Trial result
Prostate cancer
Enzalutamide Plus Venetoclax Shows Early Signals of Activity in mCRPC
In this phase Ib trial for metastatic castration-resistant prostate cancer, enzalutamide was combined with escalating doses of venetoclax (up to 800 mg/day) in a 3+3 design with no dose-limiting toxicities observed;…
- New trial
Prostate cancer
Phase III RCT Evaluates RALP with SAFE Nerve Preservation Guided by Micro-Ultrasound
This randomized trial at Mount Sinai compares standard robotic-assisted laparoscopic prostatectomy to a variant using SALINE Assisted Fascial Engorgement (SAFE) with high-resolution micro-ultrasound guidance, aiming…
NCT06945315 - New trial
Prostate cancer
Open-label Study on Lutetium-177 Vipivotide Tetraxetan Safety and Dosimetry in mCRPC
Novartis is investigating how moderate to severe renal impairment affects the biodistribution, dosimetry, and safety of Lutetium-177 vipivotide tetraxetan in progressive PSMA-positive mCRPC patients, including…
NCT06004661 - Trial result
Sarcoma and GIST
FGFR Inhibition Shuts Down Tumor Growth in SDHd GIST, Offering a New Therapeutic Avenue
In preclinical models and a Phase II trial of rogaratinib in advanced SDHd GIST, FGFR inhibitors demonstrated significant tumor growth suppression and promising clinical activity with a 41.7% partial response rate…
- New trial
Sarcoma and GIST
Phase 1a/1b Study Combines Menin Inhibition with Imatinib in Advanced GIST
Kura Oncology is assessing the safety, tolerability, and initial efficacy of oral ziftomenib combined with imatinib in adults with advanced, KIT-mutant gastrointestinal stromal tumors post-imatinib failure. This…
NCT06655246 - Trial result
Breast cancer
FALCON Final OS Analysis: Fulvestrant and Anastrozole Deliver Comparable Survival Outcomes in Advanced HR+ Breast Cancer
In the phase III FALCON trial, postmenopausal, endocrine therapy-naïve women with HR+/HER2– advanced breast cancer showed similar overall survival (median OS 44.8 vs 42.7 months; HR 0.97, P = .7579) between…
- New trial
Breast cancer
Phase 2 Umbrella Study Evaluates Boserolimab with Standard Neoadjuvant Therapy in High-Risk Early-Stage TNBC
This trial by Merck Sharp & Dohme LLC investigates whether adding boserolimab to a standard regimen of pembrolizumab, paclitaxel, and carboplatin before surgery enhances safety, tolerability, and pCR rates in newly…
NCT06829199 - New trial
Breast cancer
Phase 3 Trial Evaluates Sacituzumab Tirumotecan Alone and with Pembrolizumab in PD-L1-Low Metastatic TNBC
Merck Sharp & Dohme LLC is testing whether IV sacituzumab tirumotecan, given alone or with pembrolizumab, can improve overall survival and delay progression compared to physician’s choice chemotherapy in first-line,…
NCT06841354 - New trial
Breast cancer
Phase 1b/2 Study Combines Invikafusp Alfa with Sacituzumab Govitecan in Advanced Solid Tumors
Marengo Therapeutics is investigating the safety and efficacy of STAR0602—a TCR-targeting, bifunctional antibody-fusion molecule—in combination with the TROP2-directed ADC, sacituzumab govitecan, in patients with…
NCT06827613
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.